Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 28, 2017 | March 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2017 · Filed March 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 69,240 |
Reported balance
After 2017-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-02-28 · Grant · Acquired 26,367 · Balance 69,240 F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. F2: Due to administrative error, the Form 4 previously filed on January 6, 2017 over-reported the shares acquired by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person. |
| Common shares without par valueSEC Table I · non-derivative | Direct | 60,359 |
Reported balance
After 2017-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-02-28 · Tax withholding · Disposed 8,881 · Balance 60,359 |
| Common shares without par valueSEC Table I · non-derivative | Direct | 56,508 |
Reported balance
After 2017-03-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-03-01 · Sale · Disposed 3,851 · Balance 56,508 |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Trust | 39,413 |
Reported balance
Holding disclosure · report date 2017-02-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 39,413 F3: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
F2: Due to administrative error, the Form 4 previously filed on January 6, 2017 over-reported the shares acquired by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person.
F3: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2017 Filed Mar 2, 2017 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,851 | $45.39 | $174,796.89 |
DisclosureSEC source: 0001179110-17-003663 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,508 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,881 | $45.46 | $403,730.26 |
DisclosureSEC source: 0001179110-17-003663 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,359 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 26,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-003663 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,240 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. F2 · balance_after: Due to administrative error, the Form 4 previously filed on January 6, 2017 over-reported the shares acquired by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 205,023 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002973 · edgar.xml · derivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,023 Underlying: Common shares · 205,023 shares Expires 2027-02-16 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 68,341 on 02/17/2018, 68,341 on 02/17/2019, and 68,341 on 02/17/2020. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000677 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,874 F1 · price: On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 commonshares of Abbott. Read SEC document |
| August 31, 2016 Filed Sep 28, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 9,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030074 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 39,413 F1 · balance_after: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| August 31, 2016 Filed Sep 28, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 9,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030074 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,859 Read SEC document |
| August 31, 2016 Filed Sep 28, 2016 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030074 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,686 Read SEC document |
| July 26, 2016 Filed Jul 27, 2016 20:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 26,800 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0001179110-16-027939 · edgar.xml · derivative · entry 6 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 26,800 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 26, 2016 Filed Jul 27, 2016 20:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,500 | $43.50 | $195,750.00 |
DisclosureSEC source: 0001179110-16-027939 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,011 Read SEC document |
| July 26, 2016 Filed Jul 27, 2016 20:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,349 | $43.49 | $450,078.01 |
DisclosureSEC source: 0001179110-16-027939 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,511 Read SEC document |
| July 26, 2016 Filed Jul 27, 2016 20:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 11,951 | $43.48 | $519,629.48 |
DisclosureSEC source: 0001179110-16-027939 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,860 Read SEC document |
| July 26, 2016 Filed Jul 27, 2016 20:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 26,800 | $25.25 | $676,595.48 |
DisclosureSEC source: 0001179110-16-027939 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,600 | $38.85 | $256,377.00 |
DisclosureSEC source: 0001179110-16-020668 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,011 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,799 | $38.84 | $108,715.96 |
DisclosureSEC source: 0001179110-16-020668 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,611 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,807 | $39.52 | $189,972.64 |
DisclosureSEC source: 0001179110-16-020668 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,410 Read SEC document |
| February 29, 2016 Filed Mar 2, 2016 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-020668 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,217 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 313,926 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019893 · edgar.xml · derivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,926 Underlying: Common shares · 313,926 shares Expires 2026-02-18 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 104,642 on 02/19/2017, 104,642 on 02/19/2018, and 104,642 on 02/19/2019. Read SEC document |
| March 27, 2015 Filed Apr 2, 2015 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-005828 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 29,586 F1 · balance_after: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| March 27, 2015 Filed Apr 2, 2015 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 4,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-005828 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,184 Read SEC document |
| March 10, 2015 Filed Mar 12, 2015 21:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $46.42 | $4,642.10 |
DisclosureSEC source: 0001179110-15-004816 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,433 Read SEC document |
| March 10, 2015 Filed Mar 12, 2015 21:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,500 | $46.42 | $162,470.00 |
DisclosureSEC source: 0001179110-15-004816 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,533 Read SEC document |
| March 10, 2015 Filed Mar 12, 2015 21:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,900 | $46.41 | $459,468.90 |
DisclosureSEC source: 0001179110-15-004816 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,033 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,620 | $47.61 | $315,178.20 |
DisclosureSEC source: 0001179110-15-004040 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,933 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-004040 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,553 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2015 Filed Feb 24, 2015 22:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 181,034 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003332 · edgar.xml · derivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,034 Underlying: Common shares · 181,034 shares Expires 2025-02-19 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,345 on 2/20/16, 60,344 on 2/20/17, and 60,345 on 2/20/18. Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,982 | $39.02 | $389,497.64 |
DisclosureSEC source: 0001179110-14-004299 · edgar.xml · nonDerivative · entry 8 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,851 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $39.01 | $7,802.40 |
DisclosureSEC source: 0001179110-14-004299 · edgar.xml · nonDerivative · entry 7 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,833 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $39.01 | $11,703.00 |
DisclosureSEC source: 0001179110-14-004299 · edgar.xml · nonDerivative · entry 6 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,033 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,118 | $39.00 | $43,603.12 |
DisclosureSEC source: 0001179110-14-004299 · edgar.xml · nonDerivative · entry 5 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,333 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $39.00 | $23,400.00 |
DisclosureSEC source: 0001179110-14-004299 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,451 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,584 | $38.97 | $100,708.82 |
DisclosureSEC source: 0001179110-14-004299 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,051 Read SEC document |
| March 03, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,700 | $38.97 | $66,250.70 |
DisclosureSEC source: 0001179110-14-004299 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,635 Read SEC document |
| February 28, 2014 Filed Mar 4, 2014 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,152 | $39.79 | $324,368.08 |
DisclosureSEC source: 0001179110-14-004299 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,335 Read SEC document |
| February 28, 2014 Filed Mar 7, 2014 22:01 UTC Amendment | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 29,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-004751 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,184 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 21, 2014 Filed Feb 25, 2014 22:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 107,793 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-14-003639 · edgar.xml · derivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,793 Underlying: Common shares · 107,793 shares Expires 2024-02-20 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 35,931 on 2/21/2015, 35,931 on 2/21/2016 and 35,931 on 2/21/2017. Read SEC document |
| January 29, 2014 Filed Jan 31, 2014 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,923 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0001179110-14-001634 · edgar.xml · derivative · entry 8 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,923 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 29, 2014 Filed Jan 31, 2014 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,404 | $0.00 Strike: $31.90 | $0.00 |
DisclosureSEC source: 0001179110-14-001634 · edgar.xml · derivative · entry 7 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 5,404 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 29, 2014 Filed Jan 31, 2014 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,103 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001179110-14-001634 · edgar.xml · derivative · entry 6 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 3,103 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 29, 2014 Filed Jan 31, 2014 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 11,430 | $36.21 | $413,832.29 |
DisclosureSEC source: 0001179110-14-001634 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,487 Read SEC document |
| January 29, 2014 Filed Jan 31, 2014 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,923 | $32.60 | $95,283.95 |
DisclosureSEC source: 0001179110-14-001634 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2014 Filed Jan 31, 2014 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,404 | $31.90 | $172,394.08 |
DisclosureSEC source: 0001179110-14-001634 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2014 Filed Jan 31, 2014 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,103 | $31.26 | $97,006.30 |
DisclosureSEC source: 0001179110-14-001634 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2013 Filed May 7, 2013 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,960 | $37.06 | $146,757.60 |
DisclosureSEC source: 0001179110-13-007918 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,487 Read SEC document |
| February 28, 2013 Filed Mar 2, 2013 00:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,838 | $34.26 | $371,309.88 |
DisclosureSEC source: 0001179110-13-003904 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,447 Read SEC document |
| February 28, 2013 Filed Mar 2, 2013 00:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-003904 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,285 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 23:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 266 | $34.78 | $9,251.75 |
DisclosureSEC source: 0001179110-13-003170 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,552 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 23:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,800 | $34.78 | $97,389.60 |
DisclosureSEC source: 0001179110-13-003170 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 Read SEC document |
| February 19, 2013 Filed Feb 20, 2013 23:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,452 | $35.08 | $226,336.16 |
DisclosureSEC source: 0001179110-13-003170 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,618 Read SEC document |
| February 15, 2013 Filed Feb 20, 2013 23:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 149,600 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-13-003170 · edgar.xml · derivative · entry 4 Warmuth Michael J · CIK 0001452290 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,600 Underlying: Common shares · 149,600 shares Expires 2023-02-14 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 49,867 on 2/15/2014, 49,866 on 2/15/2015, and 49,867 on 2/15/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.